Optimizing growth in pediatric renal transplant recipients: An update
- PMID: 39697449
- PMCID: PMC11438944
- DOI: 10.5500/wjt.v14.i4.95967
Optimizing growth in pediatric renal transplant recipients: An update
Abstract
Growth retardation is a significant complication observed in pediatric renal transplant recipients, originating from a multifactorial etiology. Factors contributing to growth impairment encompass pre-transplant conditions such as primary kidney disease, malnutrition, quality of care, growth deficits at the time of transplantation, dialysis adequacy, and the use of recombinant human growth hormone. Additionally, elements related to the renal transplant itself, such as living donors, corticosteroid usage, and graft functioning, further compound the challenge. Although renal transplantation is the preferred renal replacement therapy, its impact on achieving final height and normal growth in children remains uncertain. The consequences of growth delay extend beyond the physiological realm, negatively influencing the quality of life and social conditions of pediatric renal transplant recipients, and ultimately affecting their educational and employment outcomes. Despite advancements in graft survival rates, growth retardation remains a formidable clinical concern among children undergoing renal transplantation. Major risk factors for delayed final adult height include young age at transplantation, pre-existing short stature, and the use of specific immunosuppressive drugs, particularly steroids. Effective management of growth retardation necessitates early intervention, commencing even before transplantation. Strategies involving the administration of recombinant growth hormone both pre- and post-transplant, along with protocols aimed at minimizing steroid usage, are important for achieving catch-up growth. This review provides a comprehensive outline of the multifaceted nature of growth retardation in pediatric renal transplant recipients, emphasizing the importance of early and targeted interventions to mitigate its impact on the long-term well-being of these children from birth to adolescence.
Keywords: Chronic kidney disease; Growth; Pediatric; Recombinant human growth hormone; Renal transplant recipients.
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
References
-
- Wong CS, Gipson DS, Gillen DL, Emerson S, Koepsell T, Sherrard DJ, Watkins SL, Stehman-Breen C. Anthropometric measures and risk of death in children with end-stage renal disease. Am J Kidney Dis. 2000;36:811–819. - PubMed
-
- Furth SL, Hwang W, Yang C, Neu AM, Fivush BA, Powe NR. Growth failure, risk of hospitalization and death for children with end-stage renal disease. Pediatr Nephrol. 2002;17:450–455. - PubMed
-
- Broyer M, Le Bihan C, Charbit M, Guest G, Tete MJ, Gagnadoux MF, Niaudet P. Long-term social outcome of children after kidney transplantation. Transplantation. 2004;77:1033–1037. - PubMed
-
- Mcbay R, Mcdonald R, O’hagan E, Gibson H, Simpson R. G352(P) Reach for the sky: identifying and managing growth failure in children with chronic renal insufficiency. Arch Dis Child. 2020;105 Suppl 1:A1–A23.
Publication types
LinkOut - more resources
Full Text Sources